Safety of medications and hormones used in the treatment of pediatric thyroid disorders

Paolo Beck-Peccoz, Luca Persani, Stephen Lafranchi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Levo-thyroxine (L-T4) is used to treat children with any form of hypothyroidism. In fact, L-T4 is the natural hormone and the principal product secreted by the thyroid. It is then converted into T3, the active compound at the tissue level, according to the temporary needs of the organism. Therefore, L-T4 can replace thyroid function in hypothyroid patients on a physiological basis. L-T4 administration is a safe and beneficial treatment that can be easily monitored by the concomitant measurement of TSH and free thyroid hormone levels. Antithyroid drugs (methimazole [MMI], carbimazole [CMI] and propylthiouracil [PTU]) are the initial treatment of choice for most children with hyperthyroidism, which is most commonly caused by Graves' disease. While generally similar in efficacy and safety, there are some differences. MMI and CMI have a longer half-life and so can be given once daily, improving compliance in children. At low doses, there are fewer side effects with MMI and CMI compared to PTU. Drug-related hepatitis and vasculitis are almost exclusively seen with PTU. β-adrenergic antagonists are safe adjunctive therapy. In specific situations, e.g., in preparing for thyroid surgery, iodine for a limited time is used to inhibit thyroid hormone secretion and reduce gland vascularity.

Original languageEnglish (US)
Pages (from-to)124-133
Number of pages10
JournalPediatric Endocrinology Reviews
Volume2
Issue numberSUPPL. 1
StatePublished - Nov 2004

Fingerprint

Propylthiouracil
Thyroid Gland
Hormones
Pediatrics
Thyroid Hormones
Safety
Carbimazole
Methimazole
Antithyroid Agents
Adrenergic Antagonists
Graves Disease
Hyperthyroidism
Vasculitis
Hypothyroidism
Thyroxine
Iodine
Hepatitis
Compliance
Half-Life
Therapeutics

Keywords

  • β-adrenergic antagonists
  • Antithyroid drugs
  • Children
  • Glucocorticoids
  • Hyperthyroidism
  • Hypothyroidism
  • Iodide
  • Iodinated contrast agents
  • L-thyroxine (l-T4)

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Beck-Peccoz, P., Persani, L., & Lafranchi, S. (2004). Safety of medications and hormones used in the treatment of pediatric thyroid disorders. Pediatric Endocrinology Reviews, 2(SUPPL. 1), 124-133.

Safety of medications and hormones used in the treatment of pediatric thyroid disorders. / Beck-Peccoz, Paolo; Persani, Luca; Lafranchi, Stephen.

In: Pediatric Endocrinology Reviews, Vol. 2, No. SUPPL. 1, 11.2004, p. 124-133.

Research output: Contribution to journalArticle

Beck-Peccoz, P, Persani, L & Lafranchi, S 2004, 'Safety of medications and hormones used in the treatment of pediatric thyroid disorders', Pediatric Endocrinology Reviews, vol. 2, no. SUPPL. 1, pp. 124-133.
Beck-Peccoz, Paolo ; Persani, Luca ; Lafranchi, Stephen. / Safety of medications and hormones used in the treatment of pediatric thyroid disorders. In: Pediatric Endocrinology Reviews. 2004 ; Vol. 2, No. SUPPL. 1. pp. 124-133.
@article{ef4e5f15a5ee47d88769a8a8799d0252,
title = "Safety of medications and hormones used in the treatment of pediatric thyroid disorders",
abstract = "Levo-thyroxine (L-T4) is used to treat children with any form of hypothyroidism. In fact, L-T4 is the natural hormone and the principal product secreted by the thyroid. It is then converted into T3, the active compound at the tissue level, according to the temporary needs of the organism. Therefore, L-T4 can replace thyroid function in hypothyroid patients on a physiological basis. L-T4 administration is a safe and beneficial treatment that can be easily monitored by the concomitant measurement of TSH and free thyroid hormone levels. Antithyroid drugs (methimazole [MMI], carbimazole [CMI] and propylthiouracil [PTU]) are the initial treatment of choice for most children with hyperthyroidism, which is most commonly caused by Graves' disease. While generally similar in efficacy and safety, there are some differences. MMI and CMI have a longer half-life and so can be given once daily, improving compliance in children. At low doses, there are fewer side effects with MMI and CMI compared to PTU. Drug-related hepatitis and vasculitis are almost exclusively seen with PTU. β-adrenergic antagonists are safe adjunctive therapy. In specific situations, e.g., in preparing for thyroid surgery, iodine for a limited time is used to inhibit thyroid hormone secretion and reduce gland vascularity.",
keywords = "β-adrenergic antagonists, Antithyroid drugs, Children, Glucocorticoids, Hyperthyroidism, Hypothyroidism, Iodide, Iodinated contrast agents, L-thyroxine (l-T4)",
author = "Paolo Beck-Peccoz and Luca Persani and Stephen Lafranchi",
year = "2004",
month = "11",
language = "English (US)",
volume = "2",
pages = "124--133",
journal = "Pediatric endocrinology reviews : PER",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Safety of medications and hormones used in the treatment of pediatric thyroid disorders

AU - Beck-Peccoz, Paolo

AU - Persani, Luca

AU - Lafranchi, Stephen

PY - 2004/11

Y1 - 2004/11

N2 - Levo-thyroxine (L-T4) is used to treat children with any form of hypothyroidism. In fact, L-T4 is the natural hormone and the principal product secreted by the thyroid. It is then converted into T3, the active compound at the tissue level, according to the temporary needs of the organism. Therefore, L-T4 can replace thyroid function in hypothyroid patients on a physiological basis. L-T4 administration is a safe and beneficial treatment that can be easily monitored by the concomitant measurement of TSH and free thyroid hormone levels. Antithyroid drugs (methimazole [MMI], carbimazole [CMI] and propylthiouracil [PTU]) are the initial treatment of choice for most children with hyperthyroidism, which is most commonly caused by Graves' disease. While generally similar in efficacy and safety, there are some differences. MMI and CMI have a longer half-life and so can be given once daily, improving compliance in children. At low doses, there are fewer side effects with MMI and CMI compared to PTU. Drug-related hepatitis and vasculitis are almost exclusively seen with PTU. β-adrenergic antagonists are safe adjunctive therapy. In specific situations, e.g., in preparing for thyroid surgery, iodine for a limited time is used to inhibit thyroid hormone secretion and reduce gland vascularity.

AB - Levo-thyroxine (L-T4) is used to treat children with any form of hypothyroidism. In fact, L-T4 is the natural hormone and the principal product secreted by the thyroid. It is then converted into T3, the active compound at the tissue level, according to the temporary needs of the organism. Therefore, L-T4 can replace thyroid function in hypothyroid patients on a physiological basis. L-T4 administration is a safe and beneficial treatment that can be easily monitored by the concomitant measurement of TSH and free thyroid hormone levels. Antithyroid drugs (methimazole [MMI], carbimazole [CMI] and propylthiouracil [PTU]) are the initial treatment of choice for most children with hyperthyroidism, which is most commonly caused by Graves' disease. While generally similar in efficacy and safety, there are some differences. MMI and CMI have a longer half-life and so can be given once daily, improving compliance in children. At low doses, there are fewer side effects with MMI and CMI compared to PTU. Drug-related hepatitis and vasculitis are almost exclusively seen with PTU. β-adrenergic antagonists are safe adjunctive therapy. In specific situations, e.g., in preparing for thyroid surgery, iodine for a limited time is used to inhibit thyroid hormone secretion and reduce gland vascularity.

KW - β-adrenergic antagonists

KW - Antithyroid drugs

KW - Children

KW - Glucocorticoids

KW - Hyperthyroidism

KW - Hypothyroidism

KW - Iodide

KW - Iodinated contrast agents

KW - L-thyroxine (l-T4)

UR - http://www.scopus.com/inward/record.url?scp=12344249528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344249528&partnerID=8YFLogxK

M3 - Article

C2 - 16456491

AN - SCOPUS:12344249528

VL - 2

SP - 124

EP - 133

JO - Pediatric endocrinology reviews : PER

JF - Pediatric endocrinology reviews : PER

SN - 1565-4753

IS - SUPPL. 1

ER -